pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks.
Highlights of the pCPA activity in March are:
- 5 products completed CADTH review, for a total of 16 files under consideration;
- 2 products initiated pCPA negotiations, for a total of 29 active negotiations;
- 3 negotiations completed for a total of 304 completed negotiations;
- 3 negotiations closed, for a total of 51 closed negotiations; and
- No files were closed without negotiation, for a total of 73 declined negotiations.
Files Under pCPA Consideration
5 new drug products received a CDEC recommendation or pERC notification to implement in March 2020, for a total of 16 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Darzalex | Daratumumab | Janssen | Multiple Myeloma | Conditional |
| Lokelma | sodium zirconium cyclosilicate | AstraZeneca | Hyperkalemia, adults | Do not reimburse |
| Monoferric | Iron (III) Isomaltoside 1000 | Pharmacosmos A/S | Iron deficiency anemia | Conditional |
| Onstryv | Safinamide | Valeo | Parkinson’s disease | Do not reimburse |
| Taltz | ixekizumab | Eli Lilly | Ankylosing spondylitis | Conditional |
Negotiation Initiation
The pCPA initiated 2 new negotiations in March, for a total of 29 active negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Initiation | Time to Initiate |
|---|---|---|---|---|---|---|
| Kanjinti | Trastuzumab | Amgen | early breast cancer/metastatic breast cancer/metastatic gastric cancer | N/A | 24 Mar 20 | N/A |
| Envarsus PA | Tacrolimus | Paladin | prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients | N/A | 16 Mar 20 | N/A |
Signals Decoded:
March saw the pCPA initiate negotiations for the 4th trastuzumab biosimilar (Kanjinti), while Envarsus enters pCPA negotiations after being reviewed by INESSS; recommendation issued November 2019.
Completed
The pCPA completed 3 negotiations since the last update for a total of 304 completed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiation | Close Date | Duration |
|---|---|---|---|---|---|---|
| Triamcinolone Hexacetonide | Triamcinolone Hexacetonide | Medexus | Rheumatoid Arthritis | 22 Nov 19 | 31 Mar 20 | 130 days |
| Xalkori | Crizotinib | Pfizer | ROS1-positive advanced NSCLC | 27 Aug 19 | 20 Mar 20 | 206 days |
| Januvia | Sitagliptin | Merck | Diabetes mellitus, Type 2 | 2 Nov 18 | 10 Mar 20 | 494 days |
Signals Decoded:
The pCPA and Merck have renegotiated the Januvia agreement, after over 16 months of discussions.
Closed
The pCPA closed 3 negotiations since the last update for a total of 51 closed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Engagement Letter | Close Date | Duration |
|---|---|---|---|---|---|---|
| Orfadin Oral Suspension | nitisinone | Sobi | Hereditary Tyrosinemia Type 1 | August 9, 2019 | March 30, 2020 | 234 days |
| Steglatro | ertugliflozin | Merck | Diabetes Mellitus, Type 2 | March 20, 2019 | March 31, 2020 | 377 days |
| Segluromet | ertugliflozin and metformin hydrochloride | Merck | Diabetes Mellitus, Type 2 | March 20, 2019 | March 31, 2020 | 377 days |
